Novartis Executive and Leadership Team

Sylvester Feddes, the Country President & Chief Executive Officer (Brazil) at Novartis, directs all commercial and operational activities within the South American market. Feddes oversees the implementation of global pharmaceutical strategies tailored to local regulatory environments and patient needs. By managing the regional leadership team, the Country President & Chief Executive Officer (Brazil) ensures that innovative medications reach healthcare providers and patients efficiently. This role involves navigating complex market dynamics to maintain a strong competitive position. Sylvester Feddes drives organizational performance by fostering partnerships with local health authorities and medical institutions. Through the strategic allocation of resources, the Country President & Chief Executive Officer (Brazil) supports the growth of the therapeutic portfolio. Ultimately, Feddes secures the company reputation as a leader in healthcare solutions by prioritizing access to life-saving treatments and maintaining high standards of operational excellence throughout the Brazilian pharmaceutical sector.

Francisco Martinez, the Chief Financial Officer, Operations at Novartis, directs the fiscal strategy governing global manufacturing and supply chain efficiency. Martinez manages capital allocation across pharmaceutical production facilities to ensure optimal resource utilization. By overseeing financial reporting for operational units, the Chief Financial Officer, Operations maintains strict adherence to budgetary targets while supporting the development of innovative medications. This leadership role involves constant collaboration with manufacturing heads to streamline cost structures and enhance production output. Francisco Martinez drives the financial health of the organization by implementing robust internal controls and risk management frameworks. Through precise analysis of operational expenditures, the Chief Financial Officer, Operations secures the necessary funding for research initiatives. Ultimately, Martinez ensures that financial performance aligns with the broader mission of delivering high-quality healthcare solutions to patients worldwide, fostering long-term stability and growth for the entire pharmaceutical enterprise.

Michael Heo, the Chief Financial Officer, & Distributor Markets (Malaysia, South, Asia) at Novartis, directs financial planning and distributor management across diverse Asian territories. Heo oversees the fiscal health of regional operations, ensuring that distribution networks function with maximum efficiency. By managing financial risk in emerging markets, the Chief Financial Officer, & Distributor Markets (Malaysia, South, Asia) protects the company assets while facilitating the expansion of pharmaceutical access. This role requires constant monitoring of regional economic trends to adjust pricing and supply strategies. Michael Heo drives the financial performance of the distributor network by implementing rigorous reporting standards and performance benchmarks. Through the optimization of regional supply chains, the Chief Financial Officer, & Distributor Markets (Malaysia, South, Asia) supports the consistent availability of medications. Ultimately, Heo ensures that financial operations in these critical markets remain robust, supporting the broader goal of improving patient health outcomes throughout South Asia.

Irfan Parkar, the Chief Financial Officer, Levant at Novartis, directs the financial strategy and resource management for operations across the Levant region. Parkar oversees budgeting, forecasting, and financial compliance to ensure the stability of regional pharmaceutical activities. By managing the fiscal requirements of local market expansion, the Chief Financial Officer, Levant supports the delivery of innovative healthcare solutions to diverse patient populations. This role involves constant collaboration with regional leadership to align financial goals with commercial objectives. Irfan Parkar drives the implementation of cost-efficiency programs that allow for greater investment in medical research and patient support. Through the rigorous analysis of regional market data, the Chief Financial Officer, Levant identifies opportunities for sustainable growth. Ultimately, Parkar secures the financial foundation of the company in the Levant, ensuring that resources are effectively deployed to address critical medical needs and maintain a strong presence in the regional pharmaceutical industry.

Waseephol Vuthiparum, the Chief Financial Officer, Country at Novartis, directs the financial operations and strategic planning for national-level pharmaceutical activities. Vuthiparum manages the fiscal health of the country organization, ensuring that all commercial initiatives remain within budgetary constraints. By overseeing financial reporting and internal controls, the Chief Financial Officer, Country maintains the integrity of the company financial statements. This role involves constant interaction with local leadership to support the development of market-specific healthcare solutions. Waseephol Vuthiparum drives the financial performance of the country unit by optimizing resource allocation and identifying areas for operational improvement. Through the implementation of robust financial frameworks, the Chief Financial Officer, Country supports the long-term sustainability of the business. Ultimately, Vuthiparum ensures that the financial strategy aligns with the global mission of delivering innovative medications, thereby contributing to the overall success and growth of the company within the national market.

Maria Sarmiento, the Executive Administrator & To The Country Assistant & President at Novartis, directs the operational support and administrative coordination for the country leadership team. Sarmiento manages the complex scheduling, communication, and project tracking required to maintain the efficiency of the President office. By overseeing the flow of information between departments, the Executive Administrator & To The Country Assistant & President ensures that leadership remains focused on strategic priorities. This role involves constant interaction with senior management to facilitate effective decision-making. Maria Sarmiento drives the organizational productivity by streamlining administrative processes and managing key stakeholder relationships. Through the proactive management of executive workflows, the Executive Administrator & To The Country Assistant & President supports the successful execution of national business objectives. Ultimately, Sarmiento ensures that the leadership team operates with maximum effectiveness, allowing the company to continue delivering innovative healthcare solutions and maintaining a strong market presence.

Soukaïna Mouallif, the Customer Engagement Chief of Staff (US) at Novartis, coordinates strategic initiatives to enhance healthcare provider interactions across North American markets. Mouallif aligns cross-functional teams to improve the delivery of pharmaceutical information and support services. By managing the operational cadence of the customer engagement division, the Customer Engagement Chief of Staff (US) ensures that commercial strategies translate into effective patient outcomes. This role requires constant synchronization with marketing and sales leadership to refine engagement models. Soukaïna Mouallif drives the execution of complex projects designed to strengthen relationships with medical professionals. Through the optimization of communication channels, the Customer Engagement Chief of Staff (US) facilitates a deeper understanding of therapeutic benefits among clinicians. Ultimately, Mouallif supports the expansion of the company footprint by ensuring that every customer touchpoint reflects the commitment to scientific innovation and patient-centric care within the competitive United States healthcare landscape.

Daniela Castaneda, the Immunology Director, Commercial Operations & Chief of Staff at Novartis, architects the commercial strategy for specialized immunology treatments. Castaneda manages the operational workflows that support the launch and distribution of advanced therapies. By coordinating between research departments and commercial teams, the Immunology Director, Commercial Operations & Chief of Staff ensures that clinical insights inform market access strategies. This role involves rigorous oversight of commercial performance metrics to drive patient adoption. Daniela Castaneda drives the alignment of internal resources to meet the specific needs of patients suffering from complex immunological conditions. Through the integration of data-driven decision-making, the Immunology Director, Commercial Operations & Chief of Staff optimizes the delivery of healthcare solutions. Ultimately, Castaneda strengthens the market position of the immunology portfolio by ensuring that commercial operations remain agile, efficient, and focused on delivering superior therapeutic outcomes across global regions.

Osamu Ida, the Regional Chief Marketing Officer, Head Patient Safety Quality Assurance , Ps Quality Assurance Regions & Countries, Gdd Quality Assurance (Region Japan) at Novartis, directs the marketing strategy and quality assurance protocols for the Japanese market. Ida oversees the promotion of innovative medications while ensuring that all patient safety standards meet rigorous regulatory requirements. By managing the quality assurance framework for regional operations, the Regional Chief Marketing Officer, Head Patient Safety Quality Assurance , Ps Quality Assurance Regions & Countries, Gdd Quality Assurance (Region Japan) maintains the highest levels of product integrity. This role involves constant coordination with global quality teams to implement best practices. Osamu Ida drives the commercial success of the portfolio by aligning marketing campaigns with patient safety initiatives. Through the integration of quality assurance into every stage of the product lifecycle, the Regional Chief Marketing Officer, Head Patient Safety Quality Assurance , Ps Quality Assurance Regions & Countries, Gdd Quality Assurance (Region Japan) ensures that patients receive safe and effective treatments.

Rekha Garg, the Chief Medical Officer at Novartis, directs the clinical strategy and medical oversight for the entire pharmaceutical portfolio. Garg manages the scientific integrity of research and development programs, ensuring that all treatments meet the highest standards of efficacy and safety. By overseeing the medical affairs division, the Chief Medical Officer facilitates the communication of clinical data to healthcare providers and regulatory bodies. This role involves constant collaboration with the research team to guide the development of innovative medications. Rekha Garg drives the medical vision of the company by prioritizing patient-centric research and evidence-based medicine. Through the rigorous evaluation of clinical trial results, the Chief Medical Officer ensures that the company remains at the forefront of medical innovation. Ultimately, Garg secures the reputation of the organization as a leader in healthcare by maintaining a steadfast commitment to scientific excellence and the improvement of patient outcomes across all therapeutic areas.